FDA approves changes to Byetta label

11/2/2009 | Reuters · Wall Street Journal, The

The FDA approved a revised label for diabetes drug Byetta to include reports of problems with kidney function. The decision came days after Eli Lilly and Co. and Amylin Pharmaceuticals received clearance to promote Byetta as a stand-alone treatment for Type 2 diabetes.

View Full Article in:

Reuters · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care